ストックスクリーナーアプリを入手
0.5923
1.17%
-0.0047
アフターアワーズ：
.59
-0.0023
-0.39%
前日終値:
$0.597
開ける：
$0.6
24時間の取引高:
41,435
Relative Volume:
0.18
時価総額：
$2.67M
収益：
$7,500
当期純損益:
$-9.84M
株価収益率:
-0.1034
EPS:
-5.7263
ネットキャッシュフロー:
$-9.25M
1週間 パフォーマンス:
+2.86%
1か月 パフォーマンス:
-8.10%
6か月 パフォーマンス:
-35.16%
1年 パフォーマンス:
-89.65%
1日の値動き範囲:
$0.5801
$0.60
1週間の範囲:
$0.5601
$0.61
52週間の値動き範囲:
$0.5038
$9.60
Oragenics Inc Stock (OGEN) Company Profile
名前
Oragenics Inc
セクター
電話
813-286-7900
住所
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.5923 | 2.69M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc (OGEN) 最新ニュース
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentOpen Signal Network - Newser
Oragenics Q2 2023 Earnings: Narrowing Loss Surprises, No Revenue YetFull Year Guidance - Newser
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - marketscreener.com
Oragenics (OGEN) Rallies +4.50% as Bulls Target $0.63 2026-05-20Community Buy Signals - Newser
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment - MEXC
Oragenics Highlights Investor Outreach at Micro-Cap Conference - TipRanks
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 - Yahoo Finance
Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device - TradingView
ORAGENICS PROVIDES INVESTOR UPDATE - Sahm
Oragenics (OGEN) Q2 2023 Earnings Surprise: EPS $-1.51, Up SignificantBanking Earnings Report - Newser
Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion - citybuzz -
Oragenics advances concussion drug trial, signs device LOI - Investing.com UK
Oragenics advances concussion drug trial, signs device LOI By Investing.com - Investing.com Nigeria
OGEN Technical Analysis | Trend, Signals & Chart Patterns | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
TradingKey - TradingKey
Oragenics (OGEN) continues pipeline investments amid losses; CEO discusses strategic priorities and funding outlook.Crowd Entry Points - Newser
Oragenics: Q1 Earnings Snapshot - KGW
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oragenics | 10-Q: Q1 2026 Earnings Report - Moomoo
Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases - citybuzz -
Oragenics signs letter of intent to license blood purification tech - Investing.com
Oragenics signs letter of intent to license blood purification tech By Investing.com - Investing.com Australia
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - ChartMill
Oragenics IncSigns Letter Of Intent To License Cardiodialysis From Sigyn TherapeuticsSEC Filing - TradingView
Oragenics adds second site to concussion drug trial in Australia By Investing.com - Investing.com India
Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site - MEXC
Oragenics, Inc. Opens Second Clinical Site for Phase IIa Trial of ONP-002, Evaluating Treatment for Concussion with 60 Participants - geneonline.com
Oragenics adds second site to concussion drug trial in Australia - Investing.com
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - Yahoo Finance
Oragenics shares plunge following announcement of $20 million preferred stock sale - MSN
Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Trea - GuruFocus
Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Treatment - GuruFocus
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - The Manila Times
Concussion has no approved drug; Oragenics doses 2 in trial - Stock Titan
OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
OGEN Ownership | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Earnings Recap: Is Oragenics Inc gaining market shareWeekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Oragenics Doses First Patient in Phase IIa Trial for Potential Concussion Treatment - citybuzz -
Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia - TipRanks
Oragenics Doses First Patient in Phase IIa Trial of ONP-002 for Concussion, Targeting Unmet Need in Mild Traumatic Brain Injury 1 - Minichart
Oragenics doses first patient in Phase IIa trial of ONP-002 for concussion - TradingView
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewswire
Sectors Review: Is Oragenics Inc stock technically oversold2026 Institutional & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Oragenics Inc (OGEN) 財務データ
収益
当期純利益
現金流量
EPS
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):